Mar 17, 2021
Dr. Steve Kanes, Chief Medical Officer, Sage Therapeutics takes the view that mental disorders and brain health disorders need to be treated like any other medicine. Driving this paradigm shift is the development of breakthrough zuranalone, an oral limited-time treatment to replace taking medicine chronically for those suffering from major depressive disorder. Clinical trials are showing when people do experience recurrences of MDD and episodes are treated when they occur, there are long and prolonged benefits.
@SageBiotech #postpartum #depression #MajorDepressiveDisorder #MDD